Chiron Corporation Announces Promising Data From Clinical Study Of Adjuvanted Avian Influenza Vaccine

EMERYVILLE, Calif.--(BUSINESS WIRE)--Oct. 28, 2005--Chiron Corporation (NASDAQ:CHIR) today announced preliminary promising data from a clinical study of its investigational vaccine against an H9N2 avian influenza strain that has infected a small number of people and may have the potential to cause a human pandemic. The trial was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

Back to news